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Background: Cervical squamous intra-epithelial lesions (SIL) are more frequent in HIV-positive women overall.
However the appropriate age at which to begin and end cervical cancer screening for early detection of lesions in
HIV-positive women is not clear. We assessed the age-specific prevalence of any SIL and SIL requiring colposcopy in
HIV-positive women in Cameroon.
Methods: We enrolled, interviewed and conducted conventional cervical cytology in 282 women, aged 19–68
years, initiating antiretroviral therapy in three clinics in Cameroon. In bivariable analyses, the crude relationship
between age and the presence of lesions was assessed using locally weighted regression (LOWESS) methods. In
multivariate analyses, generalized linear models with prevalence as the outcome, an identity link and a binomial
distribution, were used to estimate prevalence differences. Bias analyses were conducted to assess the potential
effect of inaccuracies in cytology.
Results: SIL were detected in 43.5% of the 276 women with satisfactory samples, 17.8% of whom had ASC-H/HSIL.
On average, women aged 26 to 59 tended to have a slightly higher prevalence of any SIL than other women
(Prevalence difference PD: 6.5%; 95%CI: -11.4, 24.4%). This PD was a function of CD4 count (heterogeneity test
p-value =0.09): amongst patients with CD4 counts less than 200cells/uL, the prevalence was higher in patients aged
26–59, while there was essentially no difference amongst women with CD4 counts greater than 200 cells/uL.
ASC-H/HSIL were present in women as young as 19 and as old as 62. Overall the prevalence of ASC-H/HSIL
increased by 0.7% (95%CI: -3.8%, 5.1%) per decade increase in age.
Conclusion: Both severe and less severe lesions were prevalent at all ages suggesting little utility of age-targeted
screening among HIV-positive women. Nevertheless, the long-term evolution of these lesions needs to be assessed
in prospective studies.Background
Cervical cancer is the second most common cancer in
women worldwide [1]. Although cervical cancer inci-
dence and mortality is higher in HIV-positive women,
resource limitations restrict the implementation of sys-
tematic screening programs in these women in develop-
ing countries. With the recent increase in access to
antiretroviral therapy HIV-positive women are expected
to live longer, potentially allowing sufficient time for* Correspondence: atashili@yahoo.ie
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reproduction in any medium, provided the orcervical cancer to develop. Targeted screening could po-
tentially alleviate the strain on resources needed to
screen these women.
Age has been a common consideration in the targeted
screening for precancerous lesions in the general popu-
lation. Current guidelines for screening the general
population of women in the United States (US) suggest
screening commence no later than age 21 years, redu-
cing the frequency of screening at age 30 among women
with previously negative cytology results and stopping
screening at age 65 (or 70 in some guidelines) [2-4].
World Health Organization (WHO) guidelines aimed
primarily at resource-limited settings are less stringent,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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annual and need not be done over the age of 65 [5].
These age considerations may not necessarily be ideal
for HIV-positive women among whom higher human
papilloma virus (HPV) prevalence, higher HPV persist-
ence, and a faster progression of lesions [6-11] could
mean an earlier occurrence and or a longer persistence
of precancerous lesions. The optimal age for screening
in HIV-positive individuals could thus be younger than
for women in the general population.
We describe here the age-specific prevalence of lesions
in HIV-positive women initiating antiretroviral therapy
in Cameroon, with the aim of estimating the minimum
age at which lesions occur, the age with maximum oc-
currence and the latest age at which lesions occur.
Methods
Study design and population
In this cross-sectional study, HIV-positive women were
recruited from three HIV-care clinics in Cameroon: the
Bamenda Provincial Hospital AIDS Treatment Center
(ATC), the Limbe Provincial Hospital ATC and the
Nylon District Hospital ATC in Douala. These are all
located in urban areas in Cameroon and provide regular
care to patients from surrounding urban areas and per-
ipheral rural areas. Consecutive HIV-positive women re-
ceiving care in these clinics, between August and
September 2008, were invited to participate in the study.
Women aged 18 years or more, who initiated HAART
within a year of study enrollment and consenting to
study procedures were eligible. Women who were either
pregnant, bleeding due to menses or had a previous total
hysterectomy were excluded. After obtaining written
consent from each participant, socio-demographic and
clinical data were collected using a structured interview,
a clinical examination and a review of medical records.
Cervical cell samples were then collected using Ayre’s
spatula, and smeared into two pre-labeled slides.
Conventional cytology slides collected were transported
to the laboratory of the Center for the Study and Control
of Communicable Diseases (CSCCD) in Yaounde, Camer-
oon where they were stained by the Papanicolau’s method
and examined under the microscope by a trained cytolo-
gist. The stained slides were observed under the micro-
scope (at 400X) and then scored according to the
Bethesda 2001 system, as unsatisfactory; negative; atypical
squamous cells of uncertain significance (ASCUS); low-
grade squamous intraepithelial lesions (LSIL); atypical
squamous cells, cannot exclude high grade lesions (ASC-
H); high-grade SIL (HSIL); or invasive cervical cancer
[12]. For quality control purposes, both research assistants
and cytologist received specific training related to the
study, two slides were made and analyzed for each patient
(the most severe result was considered the final result, incase of differences between both slides), and slides with
lesions were double-checked by a cytologist external to
the study (differences were resolved by consensus). Fur-
thermore, a subset of 10% slides were reviewed by an
experienced cytologist at the University of North Carolina
at Chapel Hill – the percentage agreement was on the
presence of lesions was 76%, (kappa=0.49) while the per-
centage agreement on lesions being ASC-H/HSIL was
60% (kappa=0.26). The potential impact of these limita-
tions with conventional cytology were assessed in sensitiv-
ity (bias) analyses [13].
The study was approved by the Cameroon National
Ethics Committee and the University of North Carolina
at Chapel Hill's Biomedical IRB (USA).Data analysis
Data collected were entered into MS Access interface on
Epi-info 2000. Statistical analysis were conducted using
SAS version 9.2 (SAS institute inc, Cary NC) and Stata
version 10 (Stata corps, Texas USA). Two outcomes
were considered for this analysis: 1) Prevalent cervical
lesions (defined as the presence of any cervical epithelial
lesions); 2) Prevalent ASC-H/HSIL. Age (in years) was
the independent predictor considered. Other covariates
considered in this analysis included marital status, edu-
cation level, parity, history of hormonal contraception,
smoking history, CD4 count, and AIDS clinical stage.
Univariable distributions of these characteristics were
determined by computing means, median and ranges
(for continuous variables) and proportions at different
levels (for categorical variables).
In bivariable analyses, the crude relationship between
each outcome and age was assessed using locally
weighted regression (LOWESS) methods with a smooth-
ing parameter of 0.5 [13]. In subsequent analyses, we
used generalized linear models with prevalence as the
outcome, an identity link and a binomial distribution, as
we sought to estimate prevalence differences [13]. We
explored coding age as a continuous variable (linear or
quadratic) or coding age as a categorical variable with
cut-offs based on the LOWESS-smoothed curve. For
each outcome, the coding of age that resulted in the best
model fit (or least deviance), as assessed by a likelihood
ratio test (for nested models) or the Akaike’s Informa-
tion criterion (for non-nested models) was selected. Age
coded as a binary variable (age 26–59 or not) had the
best fit in modeling the association of age and any le-
sion, while age coded as a continuous linear variable had
the best fit in modeling the association of age and ASC-
H/HSIL.
In multivariable analysis all covariates other than age
and the outcomes were assessed as potential modifiers
of the prevalence difference. Each covariate was coded
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ated between age and each covariate. Covariates were
considered modifiers if a likelihood ratio test of the
product interaction term had a p-value less than 0.1,
(a higher cut-off point set a priori to account for the low
power associated with tests of homogeneity) or if the
stratum-specific prevalence differences varied by 20% or
more.
Although all covariates were also considered as poten-
tial confounders, a Directed Acyclic Graph (DAG) ana-
lysis revealed that none of the variables should be
considered a confounder [13]. We attempted to math-
ematically estimate the minimum and maximum ages at
which cervical lesions are present as well as the age with
the maximum prevalence of lesions assuming a quad-
ratic relationship between age and prevalent lesions.
Only the age of maximum prevalence could however be
estimated as all other models resulted in extrapolations
beyond biologically plausible ages. Age was centered in
these models to allow for a meaningful interpretation of
all model parameters [13].Results
Altogether 282 women were enrolled in this study. Parti-
cipants’ age ranged from 19 to 68 years (with a mean of
36 years). The median CD4 count was 179 cells/micro-
liter (interquartile range: 100 to 271). SIL were detected
in 43.5% of the 276 women with satisfactory samples:
0.7% as ASCUS, 25.0% as LSIL, 14.5% as ASC-H, and
3.3% as HSIL.Prevalence of lesions by age
The age of participants with no lesions ranged from 19
to 68 (with a mean of 36.3) years while that of partici-
pants with any lesion ranged from 19 to 62 (with a mean
of 35.7) years. The prevalence of any lesion tended to in-
crease from age 19 to a peak at about 25 years (Table 1),
from which it stabilized between 40% and 50% until the
age of 60, after which it reduced among the small num-
ber of women surveyed (Figure 1).Table 1 Age-specific prevalence of cervical precancerous
epithelial lesion in 276 women initiating HAART in
Cameroon
Age
(Years)
N Prevalence of any lesion Prevalence of ASC-H/HSIL
% 95% CI % 95% CI
18-24 16 31.3 11.0, 58.7 6.3 01.6, 30.2
25-34 124 45.2 36.2, 54.3 18.5 12.1, 26.5
35-44 80 43.8 32.7, 55.3 15.0 08.0, 24.7
45-54 42 40.5 25.6, 56.7 16.7 07.0, 31.4
55-59 7 57.1 18.4, 90.1 42.9 09.9, 81.6
60+ 6 33.3 04.3, 77.7 33.3 04.3, 77.7On an average women aged 26 to 59 had a slightly
higher prevalence than relatively younger or older
women (Prevalence difference PD: 6.5%; 95%CI: -11.4,
24.4%). However this PD was a function of CD4 count
(heterogeneity test p-value =0.09). Amongst patients
with CD4 counts less than 200cells/uL, women aged
25–59 had a substantially higher prevalence (PD= 21.0%;
95% CI: -0.8%, 42.8%). In contrast, there was only a little
difference in prevalence by age among women with CD4
counts greater than 200 cells/uL (PD= −9.8%; 95%CI:
-37.8%, 18.3%).
We conducted bias analyses assessing what the true
population prevalence difference of lesions could be
considering the inaccuracies in conventional cytology.
The misclassification of the outcome resulting from
these inaccuracies was assumed to be non-differential as
the cytologist was masked from participants’ ages. Our
analysis showed that a lower cytology sensitivity or spe-
cificity would mean that the study tended to underesti-
mate the magnitude of the prevalence difference
between age groups (Figure 2). For example with a sensi-
tivity of 70% and a specificity of 90% among women with
CD4 counts less than 200cells/uL, the prevalence of
lesions in women aged 25–59 could be 35% higher than
in younger or older women. A similar sensitivity and
specificity among women with CD4 counts more than
200cells/uL, could correspond to a 16.3% lower preva-
lence of lesions in women aged 25–59 compared to
younger or older women.
Assuming a quadratic relationship between age and
the prevalence of SIL, the age with maximum prevalence
was estimated to be 34.9 (95% CI: 11.6, 58.1) years.
Prevalence of ASC-H/HSIL by age
The age of participants with ASC-H/HSIL ranged from
19 to 62 (with a mean of 36.5) years. In contrast to any
lesion, the age-specific prevalence of ASC_H/HSIL
increased slowly but more or less monotonically with
age (Figure 1). On an average, the prevalence of ASC-H/
HSIL increased by 0.7% (95%CI: -3.8%, 5.1%) per decade
increase in age. The age-specific prevalence of ASC-H/
HSIL did not appear to differ by CD4 count.
Discussion
Data on age-specific prevalence of SIL are needed if age-
targeted screening is to be considered in HIV-positive
women. In this paper, we show that while the prevalence
of SIL appeared highest in the third and fourth decades
of life, and the prevalence of ASC-H/HSIL gradually
increased with age, the prevalence of lesions did not ap-
pear to be age-limited.
The epidemiology of SIL in the general population of
(mainly HIV-negative) women has been at the origin of
age-targeted screening in these women. Studies
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Figure 1 Trends in age-specific prevalence of precancerous lesions and ASC_H/HSIL in 276 women initiating HAART in Cameroon
(estimates based on locally weighted regression models).
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lesions in young women [14-16]. Subsequent studies
showed that the peak of occurrence of precancerous
lesions was in the third to fourth decade while malignant
lesions tended to occur later in the fourth or fifth decade
[17-20]. Lesions also appeared to be less frequent in
women far past menopause [21].
In this study limited to HIV-positive women, the
prevalence of lesions was only slightly higher in all
women aged 25–59 compared to other women. This
suggests that, unlike in HIV-negative women, age only
may not be a good criterion for targeted screening. Age
differences in the prevalence of lesions, however,
appeared to depend on CD4 counts. Amongst women
with low CD4 counts, middle-aged women had a higher
prevalence than younger or older women, suggesting that
screening efforts are particularly needed in these women.
To the best of our knowledge few studies have discussed
the age-specific prevalence of lesions and severe lesions in
HIV-positive women. Unlike our study in which the
prevalence of ASC-H/HSIL lesions increased with age,
Parham et al. [22] described an inverse-U trend among
691 HIV-positive women aged 23–49 years in Zambia,
with a peak prevalence of HSIL/invasive cancer between
age 35 and 40 years. It is not clear why these findings dif-
fer but the variations in study population age, the relatively
low CD4 counts (median of 165) and slightly different out-
comes may have contributed to this difference.
While we document prevalent ASC-H/HSIL at all ages
in HIV-positive women, it is not clear what the long-term
outcome of these lesions would be and this may dependon age. It is conceivable that if lesions were less likely to
progress in younger versus older women then targeting
older women would be justified or vice versa. Prospective
studies in HIV-negative women have had inconsistent
results: while lesions were more likely to progress in older
women in some studies [23] the majority of studies noted
similar progression rates irrespective of age [24-28]. Simi-
lar studies need to be conducted in HIV-positive women
with limited access to systematic screening.
Our findings are susceptible to bias from misclassifica-
tion of outcomes as conventional cytology typically has a
low sensitivity [29]. Nonetheless, because the cytologists
were masked from participants’ age information, these
errors are expected to be independent of age (non-differ-
ential) potentially biasing our effect estimates towards
the null (resulting in an underestimate of the difference
in prevalence by age groups).
Secondly, because of the cross-sectional design of the
study, the age-specific prevalence described here reflects
the age of lesion detection and not necessarily the age of
incidence or the age-specific prevalence in the popula-
tion. Age differences in access to clinics may result in ar-
tificially increased prevalence in older women who are
more likely to be in the health care system. The latter
detection bias is however expected to be minimal in a
study population of HIV-positive women in whom ac-
cess to care is largely driven by worsening HIV disease
rather than age. Four in five women in this study had
advanced HIV diseases (WHO stage III or IV) and the
small number of women aged 50 or more than limited
the influence of these women on study estimates.
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Figure 2 Sensitivity analysis of outcome misclassification on the observed prevalence difference between age groups (26–59 versus
18–25 and 60+ years) by CD4 count.
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In conclusion, cervical precancerous lesions were preva-
lent at all ages in this population of HIV-positive
women, suggesting little utility of age-targeted screening.
A better understanding of the value of age-targeted
screening would require an assessment of the age-
specific long-term evolution of untreated non-severe
lesions and treated severe lesions using prospective
studies. The potential costs and benefits associated with
age-targeted screening will also need to be evaluated in
formal cost-effectiveness analyses.
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